High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC

Summary

The purpose of this study is to investigate whether high-dose icotinib treatment beyond disease progression is beneficial for NSCLC patients who have EGFR mutation and who have responded to EGFR TKI.

Timeline

Start

2016-11

Primary completion

2018-01

Completion

—

Drugs

Indications